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ABSTRACT
GH responses to ghrelin, GHRP-6, and GHRH in Cushing’s disease (CD) are
markedly blunted. There is no data about the effect of reduction of cortisol
levels with steroidogenesis inhibitors, like ketoconazole, on GH secretion in
CD. ACTH levels during ketoconazole treatment are controversial. The aims of
this study were to compare the GH response to ghrelin, GHRP-6, and GHRH,
and the ACTH and cortisol responses to ghrelin and GHRP-6 before and after
one month of ketoconazole treatment in 6 untreated patients with CD. Before
treatment peak GH (µg/L; mean ± SEM) after ghrelin, GHRP-6, and GHRH
administration was 10.0 ± 4.5; 3.8 ± 1.6, and 0.6 ± 0.2, respectively. After one
month of ketoconazole there was a significant decrease in urinary cortisol val-
ues (mean reduction: 75%), but GH responses did not change (7.0 ± 2.0; 3.1 ±
0.8; 0.9 ± 0.2, respectively). After treatment, there was a significant reduction
in cortisol (µg/dL) responses to ghrelin (before: 30.6 ± 5.2; after: 24.2 ± 5.1). No
significant changes in ACTH (pg/mL) responses before (ghrelin: 210.9 ± 69.9;
GHRP-6: 199.8 ± 88.8) and after treatment (ghrelin: 159.7 ± 40.3; GHRP-6: 227
± 127.2) were observed. In conclusion, after short-term ketoconazole treat-
ment there are no changes in GH or ACTH responses, despite a major
decrease of cortisol levels. A longer period of treatment might be necessary
for the recovery of pituitary function. (Arq Bras Endocrinol Metab
2007;51/7:1110-1117)
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RESUMO
Efeito do Tratamento com Ketoconazole por um Mês na Liberação de
GH, Cortisol e ACHT Após Administração de GHrelin, GHRP-6 e GHRH
em Pacientes com Síndrome de Cushing.
Na doença de Cushing (DC), as respostas do GH à ghrelina, ao GHRP-6 e ao
GHRH estão diminuídas. Não existem dados sobre o efeito da redução dos
níveis de cortisol, após cetoconazol, na secreção de GH na DC. Nessa situação,
os níveis de ACTH são variáveis. Os objetivos do estudo são comparar as
respostas do GH à administração de ghrelina, GHRP-6 e GHRH, e de ACTH e
cortisol à ghrelina e ao GHRP-6 antes e após um mês de tratamento com ceto-
conazol em 6 pacientes com DC não tratados. Antes do tratamento, o pico de
GH (µg/L; média ± EPM) após a administração de ghrelina, GHRP-6 e GHRH foi
de 10,0 ± 4,5; 3,8 ± 1,6 e 0,6 ± 0,2, respectivamente. Após um mês de ceto-
conazol, ocorreu diminuição significante do cortisol urinário (redução média:
75%), mas as respostas de GH permaneceram inalteradas (7,0 ± 2,0; 3,1 ± 0,8;
0,9 ± 0,2, respectivamente). Após o tratamento, houve redução da resposta de
cortisol (µg/dL) à ghrelina (antes: 30,6 ± 5,2; após: 24,2 ± 5,1), mas não ocor-
reram mudanças nas respostas de ACTH (pg/mL) (ghrelina antes: 210,9 ± 69,9;
após: 159,7 ± 40,3; GHRP-6 antes: 199,8 ± 88,8; após: 227 ± 127,2). Assim, o
tratamento a curto prazo com cetoconazol não modificou as respostas de GH
ou ACTH, apesar da redução do cortisol. Para a recuperação da função
hipofisária deve ser necessário um período de tratamento maior. (Arq Bras
Endocrinol Metab 2007;51/7:1110-1117)
Descritores: Ghrelina; GHRP-6; GHRH; GH; ACTH; Doença de Cushing
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GH SECRETION IS CLASSICALLY modulated by aninterplay between GHRH and SRIF. However,
several studies have suggested that GH secretagogues
(GHS) might also have a role in this process, acting at
both hypothalamic and pituitary receptors (1,2).
Ghrelin, the endogenous ligand of this receptor, is
present both in the stomach and in the hypothalamus,
mainly in the arcuate nucleus (3,4). The active form of
ghrelin is acylated and this peptide has a different
chemical structure than GHS (3). Ghrelin can cross
the blood-brain barrier (5) and is able to induce GH
release in a potent manner in animals and humans after
i.v. injection (6,7). It also increases circulating ACTH
and cortisol levels (7). The main site of action of ghre-
lin and GHS is the hypothalamus, as there is a major
decrease in their GH-releasing ability in hypothalamic-
pituitary disconnection, which also abolishes the
ACTH and cortisol rise (8,9).
It is well known that glucocorticoid excess
impairs GH secretion (10). It has been previously
shown that GH responses to several stimuli, including
ghrelin, GHRP-6, and GHRH, are severely blunted in
patients with Cushing’s disease (CD) (10-15). The
mechanisms involved in the inhibitory effect of long-
term endogenous glucocorticoid excess on GH secre-
tion are as yet unclear. High glucocorticoid levels
could interfere with hypothalamic and/or pituitary
GH-releasing pathways. A decrease in hypothalamic
GHRH secretion (16) and a direct effect of glucocor-
ticoids at the somatotroph (17) could be involved.
Patients with CD have an increased ACTH and
cortisol responsiveness to ghrelin and GHRP-6 com-
pared to normal subjects (10). This could be due to
direct effect of these peptides on GHS-R (growth hor-
mone secretagogue receptor) in the corticotroph ade-
noma (18), while in normal subjects a hypothalamic
site of action has been suggested (19).
Acute clinical interventions such as the inhibi-
tion of free fatty acid synthesis (20) and short-term
dietary restriction (19) are able to increase GH secre-
tion in CD. This suggests that the secretory ability of
the somatotroph can be restored in these patients.
However, there are controversial results about the GH
secretory state in CD after remission of hypercorti-
solism induced by transphenoidal surgery or radio-
therapy (21-27).
There are no studies evaluating GH secretion in
CD during clinical treatment of hypercortisolism with
steroidogenesis inhibitors. Ketoconazole is a steroido-
genesis inhibitor that has been used for clinical treat-
ment of hypercortisolism for two decades. This com-
pound is able to normalize cortisol levels in 70% of
adult patients with CD (28). It is a safe drug, causing
very rarely hepatic damage. Its major advantage is its
ability to lower rapidly 24-hour urinary cortisol levels,
which allows dose adjustments within the first week of
treatment (29).
Conflicting results about basal and CRH-stim-
ulated ACTH levels in patients with CD were report-
ed after ketoconazole treatment (29-35). There are no
studies about ACTH release after ghrelin and GHRP-
6 during ketoconazole use in CD.
As the findings about GH and ACTH release
during ketoconazole treatment in patients with CD
are controversial, the aims of this work were to evalu-
ate GH, ACTH, and cortisol release after ghrelin and
GHRP-6 administration before and after one month
of ketoconazole use. GHRH-induced GH release was
also studied, as this peptide stimulates GH via differ-
ent mechanisms than those used by GHS.
MATERIAL AND METHODS
Subjects
Six patients with Cushing’s disease (5 women and 1 men)
were studied (5 micro and 1 macroadenoma). Their mean
age was 34.1 ± 5.1 years (range: 19–56) and their mean
body mass index (BMI) was 27.4 ± 1.0 kg/m2 (range:
23.9–31.6). All patients were previously untreated. The
diagnosis of Cushing’s disease was established on the basis of
clinical features and standard hormonal criteria, including
increased free urinary cortisol excretion, lack of suppression
of serum cortisol after low-dose dexamethasone test (1 mg
orally overnight), normal or high basal plasma ACTH and
serum cortisol levels at 08:00 h, and positive DDAVP test.
Magnetic resonance imaging (MRI) of the sellar region
showed a pituitary adenoma in all patients. After the end of
the experimental protocol, the patients were submitted to
transphenoidal surgery and the diagnosis of ACTH-secreting
tumor was confirmed by positive ACTH immunostaining of
the excised pituitary adenoma. All patients had normal renal
function and one had secondary diabetes mellitus treated
with metformin and insulin.
Ten normal subjects (4 women and 6 men) with a
mean age of 33.5 ± 3.3 years (range: 20–47) and mean BMI
of 24.4 ± 1.1 kg/m2 (range: 19.5–30.8) were also studied.
They were free of any medication at the time of the study
protocol. The women were tested in the early follicular
phase of their menstrual cycle.
Study protocol
The experimental protocol was approved by the ethics com-
mittee of Universidade Federal de São Paulo, and all subjects
gave prior informed consent. Each subject was submitted to
three tests, in random order, with a minimum interval of 48
hours between them, either receiving ghrelin (Neosystem,
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Strasbourg, France), GHRP-6 (Bachem, San Carlos, USA)
or GHRH (1-29)NH2 (Clinalfa, Läufelfingen, Switzerland).
Patients with CD were studied before and after treatment
with ketoconazole for one month. Ketoconazole was given
at a dose of 400 mg/day initially, administered twice or
three times a day. After one week of treatment the response
to the drug was evaluated by measurements of urinary corti-
sol and the dose of ketoconazole was titrated accordingly
(300–600 mg/day).
All tests were performed after an overnight fast, and
the subjects remained recumbent throughout. At 08:00 h an
indwelling catheter was inserted into an antecubital vein and
was kept patent by a slow saline infusion. The tests started
45 minutes later. After the first blood sample, each subject
received ghrelin at a dose of 1 µg/kg i.v., GHRP-6 at the
same dose or GHRH at a dose of 100 µg i.v. Blood samples
were obtained every 15 minutes until 120 minutes for hor-
monal determinations.
Assays
Serum GH was measured in duplicate by an immunofluoro-
metric assay (Wallac, Turku, Finland). The sensitivity of the
method is 0.01 µg/L, with mean inter- and intra-assay coef-
ficients of variation (CV) of 7% and 6.7% respectively. An
immunochemiluminometric assay (Diagnostic Prod. Corpo-
ration, Los Angeles, USA) was used to measure plasma
ACTH. The sensitivity of the method is 5 pg/mL, with
mean inter- and intra-assay CV of 3.6% and 2.8% respective-
ly. Serum cortisol levels were measured in duplicate by an
imunofluorometric assay (Wallac, Turku, Finland), with sen-
sitivity of 0.2 µg/L, and mean inter and intra-assay CV of
8.2% and 6.2% respectively.
Urinary cortisol was measured by radioimmunoassay
(DSL 2100 Active Genese, Texas, USA) in 4 patients. The
sensitivity of the method is 0.3 µg/L, with mean inter- and
intra-assay CV of 9.5% and 8.4% respectively. In the other 2
patients an immunochemiluminometric assay was used
(Bayer ADVIA Centaur, Tarrytown, USA), with sensivity of
0.2 µg/L and mean inter- and intra-assay CV of 3.6% and
3.3% respectively.
Statistical analysis
Friedman’s analysis of variance was performed to compare
GH, cortisol, and ACTH levels after the injection of each
peptide and to compare GH responses in the same group.
The Wilcoxon signed rank test was used for comparisons
within the same group before and after treatment and for
analysis of ACTH and cortisol values after stimulation. The
area under the curve (AUC) was calculated by trapezoidal
integration. Undetectable GH (µg/L) and ACTH (pg/mL)
values were considered to be equal to 0.01 and 5 respective-
ly, for statistical purposes. Because of changes in the assays
during the study period, urinary cortisol values were ana-
lyzed as percentual reduction. P < 0.05 was considered sta-
tistically significant. Results are reported as mean ± S.E.M
(standard error of the mean).
RESULTS
After one month of ketoconazole treatment all
patients showed a decrease in urinary cortisol levels
(mean reduction: 75%) and in five patients (83%) these
values reached the normal range.
Before treatment, patients with CD showed
higher mean peak GH (µg/L; mean ± S.E.M) values
after ghrelin administration (10.0 ± 4.5) than after
GHRP-6 (3.8 ± 1.6) and GHRH injection (0.6 ± 0.2).
However, these responses were significantly lower
than those obtained in controls (ghrelin: 58.3 ± 12.1;
GHRP-6: 22.9 ± 4.8; GHRH: 11.3 ± 3.7) (figure 1).
After ketoconazole treatment, GH responses to
ghrelin (peak: 7.0 ± 2.0), GHRP-6 (3.1 ± 0.8), and
GHRH (0.9 ± 0.2) did not change and remained lower
than in controls (figure 1), while there was a trend to
increased GH responses to GHRH only in terms of
AUC values (before: 40 ± 12 µg/L.120 min; after: 59 ±
13; P = 0.06). The same results were obtained even
when the data was analyzed excluding the patient that
did not normalize urinary cortisol levels after treatment.
Before ketoconazole, patients with CD had simi-
lar ACTH (pg/mL) and cortisol (µg/dL) values after
ghrelin (ACTH: 210.9 ± 69.9; cortisol: 30.6 ± 5.2) and
GHRP-6 (ACTH: 199.8 ± 88.8; cortisol: 28.8 ± 5.9)
administration. Peak ACTH responses to ghrelin and
GHRP-6 in CD were higher than those obtained in con-
trols (ghrelin: 79.2 ± 26.8; GHRP-6: 23.6 ± 5.7) (figure
2). Peak cortisol values were also higher in CD compared
to controls after ghrelin (17.3 ± 1.3) and GHRP-6 (13.3
± 0.9) injection, although the latter response was only
significant in terms of AUC values (data not shown).
After ketoconazole treatment, no significant
changes in peak ACTH values after both ghrelin (159.7
± 40.3) and GHRP-6 (227 ± 127.2) injection were
observed. There was a decrease in peak cortisol response
to ghrelin (24.2 ± 5.1), which became similar to that
obtained in controls. This decrease was also observed in
cortisol values after GHRP-6 injection (23.0 ± 4.4),
although not reaching statistical significance (figure 2).
There were no changes in basal cortisol or
ACTH values after treatment. No differences in BMI
were seen before and after ketoconazole administration.
Side effects
Hunger sensation was observed in some patients after
ghrelin administration. Transient facial flushing was
also seen after ghrelin, GHRP-6, and GHRH in some
cases. None of the patients had an increase in hepatic
transaminases after ketoconazole administration. Two
patients had symptoms of adrenal insufficiency in the
first week of ketoconazole treatment.
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Figure 1. (A) Mean peak GH values after ghrelin, GHRP-6, and GHRH in controls (n = 10) and in CD (n = 6) before and after 1
month of ketoconazole treatment (mean ± S.E.M). (B) Individual GH levels after ghrelin, GHRP-6, and GHRH before and after
treatment in CD.
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Figure 2. Mean peak cortisol (A) and ACTH (B) values after ghrelin and GHRP-6 in controls (n = 10) and in CD (n = 6) before and
after 1 month of ketoconazole treatment (mean ± S.E.M).
DISCUSSION
In our patients with CD GH responses to ghrelin,
GHRP-6, and GHRH were blunted, confirming earli-
er reports by us and others (10,14,15). GH respon-
siveness to ghrelin was higher in CD and also in con-
trols, which is probably due to the greater potency of
this peptide compared to GHRP-6 and GHRH. The
mechanisms involved in the inhibition of GH release
in endogenous hypercortisolism remain unclear. It has
been previously suggested that glucocorticoid excess
inhibits hypothalamic GHRH release (14). This
steroid also downregulates human GHS-R (36).
Therefore, glucocorticoids could eventually interfere
with ghrelin/GHS-stimulated transduction mecha-
nisms at the somatotroph, with a possible additional
effect on GHS-R located in GHRH-releasing neurons
in the hypothalamus (37).
It has been previously shown that acute clinical
interventions such as the inhibition of free fatty acid
synthesis (20) and short-term dietary restriction (17)
are able to increase GH secretion in CD. This suggests
that the secretory ability of the somatotroph can be
rapidly restored. Therefore, in the present study, our
aim was to investigate if short-term treatment with
ketoconazole was able to improve the glucocorticoid-
induced GH suppression in patients with CD. In order
to avoid possible GH deficiency due to previous treat-
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ment with surgery or radiotherapy, only untreated
patients were included. To our knowledge there are no
studies evaluating GH secretion in CD after pharmaco-
logical reduction and correction of hypercortisolism.
After one month of ketoconazole treatment all
patients showed a significant reduction in urinary cor-
tisol levels, and in 83% of the cases these values reached
the normal range, as reported earlier in the literature
(28). However, there were no significant differences in
GH responses to ghrelin, GHRP-6 or GHRH before
and after treatment, although a trend to increased GH
levels after GHRH was observed. As GHS/ghrelin and
GHRH activate different pathways of GH release, this
could eventually indicate that GHRH-modulated
mechanisms are more sensitive to the rapid decrease of
circulating glucocorticoid levels. However, further
studies are necessary to confirm this hypothesis.
Several studies have evaluated the GH secretory
state in patients with CD in remission, after transsphe-
noidal surgery or radiotherapy, with controversial
results, especially in adults. It has been shown that the
decrease in GH secretion might persist for a long time
in the pediatric population. GH responsiveness to argi-
nine and L-dopa and 24 h GH secretion are decreased
in children and young adults with CD for at least one
year after successful transsphenoidal surgery (24). In
another study, 31% of the children with CD, cured by
surgery and, in some cases, additional radiotherapy
had severe GH deficiency after insulin-induced hypo-
glycemia while 54% had subnormal GH responses
(peak GH between 3 and 10 µg/L) after 9 to 108
months of follow-up (38).
In adults results are less uniform. Improvement
or normalization of GH responses to hypoglycemia
have been shown in 30% to 100% of cases of patients
with CD in remission in several large series (21-23).
This variability could be due to different GH cut off
values for GH deficiency and also to the type of treat-
ment used. Patients submitted to radiotherapy had
lower GH responses, probably due to pituitary dam-
age, while 75% of the cases submitted to transsphe-
noidal surgery had recovery of GH responses (21).
Interestingly, all patients with CD submitted to
adrenalectomy in this study normalized GH responses
to hypoglycemia. Moreover, it has been shown that
GH responses to GHRH in patients with CD reverted
to normal 5 to 34 years after adrenalectomy (39).
Therefore, correction of hypercortisolism may lead to
restoration of GH secretion if somatotrophs are intact.
However, our results suggest that it is likely that
longer periods of normocortisolism are necessary for
the recovery of normal GH secretory status also in
adults. Indeed, it has been shown that 59% of patients
with CD in remission after transsphenoidal surgery
had severe GH deficiency at an early assessment (25).
However, after two years only 22% remained severely
GH deficient. This is supported by another study
which shows that patients with long-term remission of
CD (mean of 8.2 years) had normal 24-hour GH
secretion when compared to controls (26).
Recently, Tzanela et al. (27) found restoration
of GH response to GHRH plus pyridostigminine, and
also, in some cases, to hypoglycemia in 50% of patients
with Cushing’s syndrome in remission for 6 months,
while 75% of them had normal GH responses after 18
months of follow-up. These results might explain our
findings and support the hypothesis that a longer peri-
od of normocortisolism might be necessary for the
recovery of GH secretory ability in these patients.
As previously demonstrated by us and by others
(10,14,15), our patients with CD showed exaggerated
cortisol and ACTH responses to ghrelin and GHRP-
6. This might be due to a direct effect of these pep-
tides on GHS-R in the tumor (18), although other
mechanisms could be involved (40).
Despite a significant decrease in urinary cortisol
values in all patients (mean reduction: 75%) and nor-
malization in 83% of them, there was no significant
reduction in basal serum cortisol levels after one month
of ketoconazole treatment. Our data confirms previous
reports of slight serum cortisol decrease in the first
weeks (1 to 6) of ketoconazole use (32-34), although a
marked and significant reduction in urinary cortisol lev-
els has already been described in the first week of treat-
ment (31-33). This discrepancy might occur because of
fluctuations in serum cortisol levels related to the timing
of the last dose of ketoconazole, as this compound has
a short half-life and a serum peak 2 hours after its inges-
tion. Progressive and significant reduction in basal
serum cortisol levels after more prolonged periods of
time were reported by some authors (29,31,32).
Interestingly, in our study cortisol responses to
ghrelin and GHRP-6 decreased after treatment, which
shows the potent inhibition of steroid synthesis by
ketoconazole. It has also been demonstrated that cor-
tisol responses to CRH are decreased after ketocona-
zole use (32,34).
After one month of ketoconazole treatment our
patients showed no changes in basal ACTH levels.
Although an increase in basal ACTH levels during
chronic ketoconazole administration is seen in normal
subjects (41), conflicting results were reported in
patients with CD. It has been shown that in patients with
CD basal ACTH levels remain unchanged (30-33,42),
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increase (34), and even decrease (29,35) after ketocona-
zole treatment. In vitro studies were performed in order
to verify a possible direct effect of ketoconazole on pitu-
itary cells. However, results in cultures of normal rat
pituitary cells were controversial. Burrin et al. (43)
showed lack of effect of ketoconazole on ACTH release,
while Stalla et al. (44) found a decrease in ACTH secre-
tion, POMC mRNA and AMPc levels in these cells, sug-
gesting a direct inhibition of the adenylcyclase system. In
human pituitary adenoma cells from three patients with
Nelson’s syndrome, ketoconazole induced a decrease in
the surface of endoplasmatic reticulum, in the density of
secretion granules and of ACTH release (45). The clini-
cal significance of these findings has never been estab-
lished, and a direct pituitary effect of ketoconazole in CD
seems unlikely (29).
In our study patients with CD had no changes
in the ACTH responses to ghrelin or GHRP-6 after
one month of ketoconazole treatment. In the litera-
ture, data about ACTH responses to CRH during
ketoconazole use in CD are few and controversial.
Boscaro et al. (34) reported an increased ACTH
response to CRH after 4 to 6 weeks of ketoconazole
treatment, while Loli et al. (32) showed no changes in
this response after 3 to 7 months of treatment.
These discrepant patterns of ACTH release dur-
ing ketoconazole treatment in CD could be explained
by the degree or duration of the cortisol inhibition.
Theoretically, if cortisol levels decrease to subnormals
levels or if cortisol inhibition is maintained for a pro-
longed period of time, there could be a compensatory
rise of circulating ACTH released from normal corti-
cotrophs. On the other hand, if cortisol levels are in the
normal range or in the upper limit of the normality,
probably they will not be a stimulus for the HPA axis,
and ACTH levels will not change. A glucocorticoid
agonist action of ketoconazole in the corticotrophs has
been suggested, which would prevent the rise in plasma
ACTH when cortisol falls (32). Therefore, the mecha-
nisms that prevent the rise in ACTH levels during inhi-
bition of cortisol secretion in patients with CD during
ketoconazole treatment remain unclear.
In summary, our study shows that one month of
ketoconazole treatment in patients with CD is not able
to increase GH release after ghrelin, GHRP-6, and
GHRH stimulation, despite a major reduction in urinary
cortisol values. Our data also shows that basal plasma
ACTH and its response to ghrelin and GHRP-6 do not
change, although cortisol responses to these peptides
decrease after treatment. Further studies are necessary to
evaluate the effects of a more prolonged period of eucor-
tisolism on GH and ACTH release in patients with CD.
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